Icatibant Sandoz

Icatibant, the active ingredient in Icatibant Sandoz, is a bradykinin B2 receptor antagonist presented as an injection solution for subcutaneous use. It is indicated for the treatment of hereditary angioedema attacks in patients with a confirmed diagnosis, providing rapid symptom relief by blocking bradykinin‑mediated vascular effects.

GNH USA supplies Icatibant Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Icatibant is used to manage hereditary angioedema, a disorder driven by excessive bradykinin activity.

- Hereditary angioedema (HAE) attacks: provides rapid reduction of swelling by competitively blocking the bradykinin B2 receptor.

Icatibant may cause a range of adverse reactions, most of which are related to the injection site or systemic exposure.

Common Side Effects: - Injection site pain: mild to moderate discomfort at the injection site. - Redness: localized erythema around the injection area. - Swelling: transient edema at the site of administration. - Nausea: occasional feeling of queasiness. - Headache: mild to moderate headache. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reaction: rash, itching, or urticaria indicating an allergic response. - Anaphylaxis: rare but severe systemic allergic reaction requiring immediate medical attention. - Angioedema: paradoxical swelling of face, lips, or airway. - Severe hypotension: marked drop in blood pressure. - Thrombocytopenia: low platelet count observed in rare cases.

When prescribing Icatibant, clinicians should consider several precautionary measures to ensure safe use.

- Contraindication: known hypersensitivity to icatibant or any excipients. - Pregnancy: safety not established; use only if potential benefit justifies potential risk. - Breastfeeding: unknown excretion; weigh benefits against potential infant exposure. - Renal impairment: monitor closely as clearance may be reduced. - Concomitant ACE inhibitor therapy: may increase bradykinin levels; assess risk of angioedema. - Storage: Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibant can interact with other medicines that influence bradykinin pathways or cardiovascular function.

Major Interactions (Avoid): - ACE inhibitors: may augment bradykinin levels and increase risk of angioedema. - Neprilysin inhibitors (e.g., sacubitril): elevate bradykinin and could diminish icatibant efficacy. - Estrogen‑containing oral contraceptives: may raise bradykinin and heighten angioedema risk.

Moderate Interactions (Monitor Closely): - NSAIDs: can exacerbate swelling if angioedema occurs. - Diuretics: may affect blood pressure when combined with icatibant‑induced vasodilation. - Other antihypertensives: monitor for additive hypotensive effects.